Promoter holding
64.27%
LS
Lasa Supergenerics Limited - Due diligence report
A 360° intelligence report on Lasa Supergenerics: trust score, financial health, credit view, compliance, directors, growth and distress sig…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Lasa Supergenerics — 360° Intelligence Report
Generated from MCA filings & public records76/100
Trust Score
Low Risk
Lasa Supergenerics is assessed as Low Risk with a Trust Score of 76/100. Lasa Supergenerics is an active public limited indian non-government company incorporated in 2016, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 15 Aug 2026 from the latest processed filings. Lasa Supergenerics Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
76/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
62/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
65/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
50/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
- Moderate gearing (D/E 38%).
Charges position: 0 open (-) · 3 satisfied (84.64 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Axis Bank Limited | 1 | 48.0 cr |
| Others | 2 | 48.0 cr |
Compliance Score: 62/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 4 court forum(s).
- 2 auditor resignation(s) filed - latest: Ramanand & Associates on 2018-05-15.
- Delayed payments to MSME suppliers disclosed (95 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| MANALI ROOP BHAGTANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Umesh Shankar Pawar | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Mitti Jain | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARDESH RAJA TOLANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| EKTA AVTAR GURNASINGHANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| OMKAR HERLEKAR PRAVIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AJAY HARESHLAL SUKHWANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Mitti Mitesh Jain | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Prathmesh Prakash Chalke | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Varsha Pravin Joshi | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Ketan Bhau Songal | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Pravin Gadalya Lachake | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Yogesh Hari Ughada | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rekha Hemant Wakh | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Ganesh Suresh Potdar | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 15 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Omkar Speciality Chemicals Limited
Subsidiaries
-
Group entities
-
Capital events
5 allotment(s) · 0 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Omkar Speciality Chemicals Limited | Holding Company | 74.00% |
Key managerial personnel: Umesh Shankar Pawar (Whole-time director) · OMKAR HERLEKAR PRAVIN (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 50 · Distress 90
Growth signals & trust indicators
Latest year revenue grew 1.42.
Operating for 10+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 3.14 cr.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence75/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment60/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view62/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events02 Jan 2026
Director appointed
Ganesh Suresh Potdar (Additional Director)
30 Sep 2025
Last AGM held
Annual general meeting
04 Aug 2025
Director appointed
Ketan Bhau Songal (Director)
Director appointed
Pravin Gadalya Lachake (Director)
Director appointed
Yogesh Hari Ughada (Director)
Director appointed
Rekha Hemant Wakh (Director)
21 May 2025
Director appointed
Prathmesh Prakash Chalke (Additional Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
01 Aug 2024
Director appointed
Varsha Pravin Joshi (Cfo)
25 Apr 2024
Director ceased
RAVISHANKAR RAMPRASAD KABRA
08 Mar 2024
Director appointed
Umesh Shankar Pawar (Whole-time director)
02 Dec 2023
Charge satisfied
Axis Bank Limited
19 Apr 2023
Director appointed
Mitti Mitesh Jain (Company Secretary)
21 Mar 2023
Director appointed
Mitti Jain (Company Secretary)
05 Jan 2023
Securities allotted
9428571 Equity Shares - 9.43 cr raised
10
Key Observations
Auto-generated from the data aboveRevenue declined 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - manageable leverage.
Net worth is positive.
15 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 3 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Valtris Specialty Chemicals India Private Limited | U24233MH2014PTC255644 | Mumbai, Maharashtra, India |
| Murli Krishna Pharma | U24230PN2004PTC206917 | Pune, Maharashtra, India |
| Ghaziabad Organics Limited | U15511DL1996PLC075204 | Delhi, Delhi, India |
| Canton Laboratories Private Limited | U24110GJ2005PTC045571 | Vadodara, Gujarat, India |
| Sol | L72900TG1998PLC030463 | Hyderabad, Telangana, India |
| Bafna Pharma | L24294TN1995PLC030698 | Madras 600 001, Tamil Nadu, India |
| Prime Pharmaceuticals Private Limited | U24231MH1995PTC092543 | Mumbai, Maharashtra, India |
| Zydus Cadila | U24290GJ2019PLC111689 | Ahmedabad, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Lasa Supergenerics before audits and certifications: compliance score 62/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Lasa Supergenerics: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 50/100, margin trends, ownership structure and peer set for Lasa Supergenerics - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 76/100, distress signals and MSME payment-delay disclosures - know whether Lasa Supergenerics pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Lasa Supergenerics - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Lasa Supergenerics an active company?
Lasa Supergenerics has MCA status “Active” with a compliance score of 62/100 (Moderate).
Is Lasa Supergenerics financially healthy?
Lasa Supergenerics has a Financial Health Score of 65/100 (Moderate) based on its filed financial statements.
Should I do business with Lasa Supergenerics?
Its overall Trust Score is 76/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Lasa Supergenerics?
The ultimate holding entity is Omkar Speciality Chemicals Limited. 15 active director(s) are on record.
Does Lasa Supergenerics have loans or charges against its assets?
No open charges - all 3 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Lasa Supergenerics up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 62/100 (Moderate).
Is it risky to lend to Lasa Supergenerics?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
